MYIA
NBIX icon

Mount Yale Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Mount Yale Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-768
Closed -$96.5K – 1261
2025
Q2 		$96.5K Buy
+768
New +$88.1K 0.01% 667
2023
Q2 		– Sell
-5,787
Closed -$586K – 503
2023
Q1 		$586K Sell
5,787
-721
-11% -$75K 0.07% 274
2022
Q4 		$777K Sell
6,508
-1,475
-18% -$173K 0.09% 231
2022
Q3 		$848K Sell
7,983
-215
-3% -$21.8K 0.11% 191
2022
Q2 		$799K Sell
8,198
-484
-6% -$44.7K 0.1% 202
2022
Q1 		$814K Buy
+8,682
New +$736K 0.09% 229
2021
Q4 		– Sell
-6,532
Closed -$626K – 485
2021
Q3 		$626K Buy
6,532
+48
+0.7% +$4.53K 0.07% 242
2021
Q2 		$631K Buy
6,484
+124
+2% +$11.9K 0.08% 240
2021
Q1 		$619K Buy
+6,360
New +$667K 0.08% 233
2020
Q4 		– Sell
-5,080
Closed -$488K – 415
2020
Q3 		$488K Buy
+5,080
New +$588K 0.07% 246

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mount Yale Investment Advisors's NBIX Position: Q3 2025 in Review

Mount Yale Investment Advisors sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 768 shares — an estimated $96.5K sold.

Mount Yale Investment Advisors first reported a position in NBIX in Q3 2020 and held it in 10 quarters. The position peaked at $848K in Q3 2022. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Mount Yale Investment Advisors reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 768 Neurocrine Biosciences shares in Q3 2025, an estimated $96.5K.
  • Mount Yale Investment Advisors first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 10 quarters.
  • Mount Yale Investment Advisors's Neurocrine Biosciences position peaked at $848K in Q3 2022.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Mount Yale Investment Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.